NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

New Publication: Reaksi Drug Safety News - Issue 4/2017

Kadar pengguna: 1 / 5

bintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 

REAKSI Drug Safety News,

Issue 4/2017, Vol. 36

 

  • Hyoscine Butylbromide Injection: Risk of Serious Adverse Effects in Patients with Underlying Cardiac Disease
  • Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

 



 
 
  DOWNLOAD PDF


 

 

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Khamis 19 September 2024, 10:34:28.

Search